Added $140. Down because we are too high to GS target, analyst has been wrong from $50 to $140s
Again people are BLINDLY shorting the GS list of "overvalued" stocks & all the list is downside to Goldman Target...Terence Flynn (worst bio analyst in industry imo) has had low targets & has been neutral since $50s. Add --
Yes - you know if this was a well thought out list - with specific reasons why fundamentally this company will not perform - declining margins, pipeline misses, sales declines, less drugs to be sold because of generics - well u give them their day - but CELG is the opposite - increasing margins, a string of pipeline success, going from one billion $ a yr drug to 5, amazing partnerships, billions in buybacks, best EPS growth and lowest PEG in the industry, best CFO on the planet.....
Problem is this list is SIMPLY downside to GS target - they don't disclose that they have been WRONG since the 50s, that Terrence Flynn had a neutral on this all the way from $50 to $149....that his ALWAYS WRONG targets - have been embarrassingly raised while keeping his neutral to follow the already attained runs in CELG stock... He is quite simply the worst biotech analyst on the street - no ones targets have been more wrong - his neutral since $50 is more embarassing - and yet THE DOWNSIDE TO HIS TARGET is why this is on the list....BUY WITH BOTH FISTS! (more on this on InvestorVillage CELG board)